Biosimilar Pipeline | Amgen Biosimilars
CLEAR

Inflammation

Hematology / Oncology

Our Pipeline

Inflammation

Hematology / Oncology

ABP 654 (biosimilar STELARA®)

ABP 654 (ustekinumab), a biosimilar candidate to STELARA®, is a monoclonal antibody that inhibits
IL-12 and IL-23.

ABP 938 (biosimilar EYLEA®)

ABP 938 (aflibercept), a biosimilar candidate to EYLEA®, is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.

ABP 959 (biosimilar Soliris®)

ABP 959 (eculizumab), a biosimilar candidate to Soliris®, is a monoclonal antibody that specifically binds to the complement protein C5.

Next: FDA-Approved Products Next: clinical trials